JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 116 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $100,000 | -6.5% | 14,800 | +15.6% | 0.00% | 0.0% |
| Q4 2021 | $107,000 | +37.2% | 12,800 | +12.3% | 0.00% | +50.0% |
| Q2 2021 | $78,000 | +3800.0% | 11,400 | +5600.0% | 0.00% | – |
| Q3 2020 | $2,000 | -94.7% | 200 | -95.3% | 0.00% | -100.0% |
| Q4 2019 | $38,000 | +81.0% | 4,300 | +30.6% | 0.00% | 0.0% |
| Q3 2018 | $21,000 | +16.7% | 3,293 | +43.2% | 0.00% | 0.0% |
| Q2 2018 | $18,000 | – | 2,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |